• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka

Applied Pharmacokinetics and Pharmacodynamics

Principles of Therapeutic Drug Monitoring

9780781744317
283,50 zł
255,15 zł Zniżka 28,35 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 255,15 zł
Ilość
Produkt niedostępny
Nakład wyczerpany (niedostępny u wydawcy)

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis

The definitive advanced-level clinical pharmacokinetics text is now in its Fourth Edition, with new emphasis on the relationship between pharmacokinetics and pharmacodynamics. Written by 70 leading researchers and practitioners, this book is a rigorous yet practical text on the application of pharmacokinetic methods, pharmacodynamic principles, and pharmacotherapeutic data for optimal, individualized drug therapy.

This edition includes case studies that apply concepts to actual patient problems. New chapters cover tacrolimus, mycophenolic acid, sirolimus, antipsychotics, and critical evaluation of therapeutic drug monitoring methods. Other new features include more drawings and reference tables and an appendix on outcome studies with therapeutic drug monitoring.

Szczegóły produktu
42189
9780781744317
9780781744317

Opis

Rok wydania
2005
Numer wydania
4
Oprawa
miękka foliowana
Liczba stron
867
Wymiary (mm)
216 x 279
Waga (g)
1851
  • PART I:: BASIC CONCEPTS AND PRINCIPLES 1

  • General Principles of Clinical Pharmacokinetics 3
    William E. Evans

  • Guidelines for Collection and Analysis of Pharmacokinetic Data 8
    William J. Jusko

  • Critical Evaluation of Methods for Therapeutic Drug Monitoring 30
    Victor W. Armstrong and Michael Oellerich

  • Analysis of Pharmacokinetic Data for Individualizing Drug Dosage Regimens 40
    John H. Rodman, David Z. DArgenio, and Carl C. Peck

  • Pharmacodynamics 60
    Richard L. Lalonde

  • Influence of Protein Binding and Use of Unbound (Free) Drug Concentrations 82
    Janis J. MacKichan

  • Drug Metabolism, Transport, and the Influence of Hepatic Disease 121
    Angela D.M. Kashuba, Joohyun J. Park, Adam M. Persky, and Kim L.R. Brouwer

  • Application of Pharmacogenetic Principles to Clinical Pharmacology 165
    Mark W. Linder, William E. Evans, and Howard L. McLeod

  • Influence of Renal Function and Dialysis on Drug Disposition 187
    Gary R. Matzke and Thomas J. Comstock

  • Special Pharmacokinetic and Pharmacodynamic Considerations in Children 213
    Holly D. Maples, Laura P. James, and Cindy D. Stowe

  • Special Pharmacokinetic Considerations in the Obese 231 Robert A. Blouin and Mary H.H. Ensom

  • Dietary Influences on Drug Disposition 242
    Mary H.H. Ensom and Robert A. Blouin

    PART II:: MONITORED DRUGS 257

  • Asthma Management 259
    Glenn J. Whelan and Stanley J. Szefler

  • Aminoglycosides 285
    Jerome J. Schentag, Alison K. Meagher, and Roger W. Jelliffe

  • Vancomycin 328
    Pamela A. Moise-Broder

  • Microbiologic, Clinical, and Economic Outcomes of Dual Individualized Dosing of Antimicrobial Agents 341
    Joseph A. Paladino and Jerome J. Schentag

  • Antivirals for HIV 354
    Craig R. Rayner, Michael J. Dooley, and Roger L. Nation

  • Digoxin 410
    Jerome J. Schentag, Anthony J. Bang, and Jennifer L. Kozinski-Tober

  • Clinical Pharmacokinetics of Oral Antiarrhythmic Drugs 440
    Jerry L. Bauman, Harumi Takahashi, and James H. Fischer

  • Phenytoin 463
    Michael E. Winter and Thomas N. Tozer

  • Antiepileptic Drugs 491
    William R. Garnett, Gail D. Anderson, and Rebeccah J. Collins

  • Cyclosporine 512
    Atholl Johnston and David W. Holt

  • Tacrolimus 529
    Uwe Christians, Taveesak Pokaiyavanichkul, and Laurence Chan

  • Mycophenolic Acid 563
    Arthur Nawrocki, Magdalena Korecka, Sandra Solari, Juseop Kang, and Leslie M. Shaw

  • Sirolimus 595
    Barry D. Kahan and Kimberly L. Napoli

  • Anticancer Agents 617
    William P. Petros and William E. Evans

  • Heparin—UFH and LMWH 637
    Keith A. Rodvold, Sharon M. Erdman, Kelly A. Sprandel, Robert J. Cipolle, and Eleanor S. Pollak

  • Warfarin 715
    Stuart T. Haines, Thomas Dowling, and R. Donald Harvey, III

  • Nonsteroidal Anti-Inflammatory Drugs and Coxibs 752
    Tilo Grosser

  • Cyclic Antidepressants 781
    C. Lindsay DeVane

  • Lithium 798
    Tawny L. Bettinger and M. Lynn Crismon

  • Antipsychotics 813
    James M. Perel and Michael W. Jann

    Appendix:: A Critical Assessment of the Outcomes of Therapeutic Drug Monitoring 839
    Mary H.H. Ensom and Michael E. Burton

    Index 849
Komentarze (0)